CCR6 and myeloid sarcoma: Furthermore, MS patients presented with significant decreases in CCR6+ ILC1 and ILC2 but not ILC3 proportions at prior (Figure 5b, ILC1, P = 0.004; ILC2, P = 0.0072 and Supplementary figure 3a) and post2 (Figure 5b, ILC1, P = 0.0042; ILC2, P = 0.0164 and Supplementary figure 3a) when compared to non‐MS controls.